IQVIA Holdings Inc. (NYSE:IQV) Shares Purchased by Magnolia Capital Advisors LLC

Magnolia Capital Advisors LLC boosted its stake in IQVIA Holdings Inc. (NYSE:IQV) by 2.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,625 shares of the medical research company’s stock after buying an additional 74 shares during the period. Magnolia Capital Advisors LLC’s holdings in IQVIA were worth $516,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in IQV. FMR LLC increased its holdings in shares of IQVIA by 38.7% during the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock valued at $684,213,000 after purchasing an additional 804,963 shares during the period. B. Metzler seel. Sohn & Co. Holding AG acquired a new position in shares of IQVIA during the third quarter valued at $147,683,000. JPMorgan Chase & Co. increased its holdings in shares of IQVIA by 46.2% during the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after purchasing an additional 583,396 shares during the period. Nordea Investment Management AB increased its holdings in shares of IQVIA by 47.4% during the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after purchasing an additional 452,029 shares during the period. Finally, KBC Group NV increased its holdings in shares of IQVIA by 68.5% during the fourth quarter. KBC Group NV now owns 616,299 shares of the medical research company’s stock valued at $121,109,000 after purchasing an additional 250,458 shares during the period. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Stock Down 0.2 %

IQV opened at $201.34 on Monday. IQVIA Holdings Inc. has a fifty-two week low of $187.62 and a fifty-two week high of $261.73. The business has a 50-day moving average of $200.41 and a 200-day moving average of $220.39. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The company has a market capitalization of $36.54 billion, a PE ratio of 26.42, a price-to-earnings-growth ratio of 2.15 and a beta of 1.48.

Analysts Set New Price Targets

A number of research analysts recently issued reports on IQV shares. Stephens started coverage on IQVIA in a report on Friday, December 20th. They set an “overweight” rating and a $250.00 target price on the stock. Redburn Atlantic started coverage on IQVIA in a report on Monday, October 14th. They set a “buy” rating and a $276.00 target price on the stock. StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a report on Thursday, November 28th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $270.00 target price on shares of IQVIA in a report on Wednesday, December 11th. Finally, Bank of America lowered their target price on IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a report on Friday, December 13th. Four research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $255.71.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.